IL222841B - Cadherin-11 antagonist for the treatment of leprosy - Google Patents

Cadherin-11 antagonist for the treatment of leprosy

Info

Publication number
IL222841B
IL222841B IL222841A IL22284112A IL222841B IL 222841 B IL222841 B IL 222841B IL 222841 A IL222841 A IL 222841A IL 22284112 A IL22284112 A IL 22284112A IL 222841 B IL222841 B IL 222841B
Authority
IL
Israel
Prior art keywords
cadherin
fibrosis
antagonist
treatment
Prior art date
Application number
IL222841A
Other languages
English (en)
Hebrew (he)
Other versions
IL222841A0 (en
Original Assignee
Univ Texas
Brigham & Womens Hospital Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Texas, Brigham & Womens Hospital Inc filed Critical Univ Texas
Publication of IL222841A0 publication Critical patent/IL222841A0/en
Publication of IL222841B publication Critical patent/IL222841B/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/70—Mechanisms involved in disease identification
    • G01N2800/7052—Fibrosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
IL222841A 2010-05-04 2012-11-04 Cadherin-11 antagonist for the treatment of leprosy IL222841B (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US33135510P 2010-05-04 2010-05-04
US33135710P 2010-05-04 2010-05-04
PCT/US2011/035110 WO2011140173A1 (en) 2010-05-04 2011-05-04 Detection and treatment of fibrosis

Publications (2)

Publication Number Publication Date
IL222841A0 IL222841A0 (en) 2012-12-31
IL222841B true IL222841B (en) 2018-07-31

Family

ID=44904050

Family Applications (2)

Application Number Title Priority Date Filing Date
IL222841A IL222841B (en) 2010-05-04 2012-11-04 Cadherin-11 antagonist for the treatment of leprosy
IL265950A IL265950A (en) 2010-05-04 2019-04-10 Detection and treatment of leprosy

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL265950A IL265950A (en) 2010-05-04 2019-04-10 Detection and treatment of leprosy

Country Status (8)

Country Link
EP (2) EP3138915A1 (enExample)
JP (3) JP5911848B2 (enExample)
KR (2) KR20130107203A (enExample)
AU (3) AU2011248184B2 (enExample)
CA (1) CA2805267C (enExample)
ES (1) ES2596431T3 (enExample)
IL (2) IL222841B (enExample)
WO (1) WO2011140173A1 (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2015201254A1 (en) * 2010-06-04 2015-04-16 The Brigham And Women's Hospital, Inc. Treatment of inflammatory disorders
US20130209476A1 (en) * 2010-06-04 2013-08-15 The Brigham And Women's Hospital Inc. Treatment of inflammatory disorders
CN104203280A (zh) * 2012-03-27 2014-12-10 诺华股份有限公司 纤维化的治疗
KR101497935B1 (ko) * 2013-04-19 2015-03-03 경북대학교 산학협력단 루테올린을 유효성분으로 포함하는 섬유증의 예방 또는 치료용 조성물
US11097005B2 (en) 2014-12-15 2021-08-24 The Brigham And Women's Hospital, Inc. Use of cadherin-11 antagonists to treat metabolic disorders and/or increase insulin sensitivity
WO2021256837A1 (ko) 2020-06-15 2021-12-23 인제대학교 산학협력단 신장 질환 진단 또는 치료용 조성물
KR102404883B1 (ko) * 2020-11-30 2022-06-07 (주)이노보테라퓨틱스 벤즈브로마론을 포함하는 켈로이드 또는 비대흉터 예방 또는 치료용 약학 조성물
WO2023034803A1 (en) * 2021-08-30 2023-03-09 The Brigham And Women's Hospital, Inc. Methods for treatment of fibrosis
ES2957479B2 (es) 2022-06-07 2025-07-28 Baigene S L Metodo de obtencion de datos utiles para la prediccion del riesgo de un sujeto de sufrir fibrosis

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3854480A (en) 1969-04-01 1974-12-17 Alza Corp Drug-delivery system
US4355023A (en) 1980-09-30 1982-10-19 The Massachusetts General Hospital Antibody fragment compositions and process
US4675189A (en) 1980-11-18 1987-06-23 Syntex (U.S.A.) Inc. Microencapsulation of water soluble active polypeptides
US4470925A (en) 1982-05-05 1984-09-11 E. I. Du Pont De Nemours And Company Immunoglobulin half-molecules and process for producing hybrid antibodies
US4462334A (en) 1982-08-19 1984-07-31 Kim Ho K Solar animal structure
US4452775A (en) 1982-12-03 1984-06-05 Syntex (U.S.A.) Inc. Cholesterol matrix delivery system for sustained release of macromolecules
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
US5565354A (en) 1986-09-05 1996-10-15 Sandoz Ltd. Production of human monoclonal antibodies specific for hepatitis B surface antigen
US5075109A (en) 1986-10-24 1991-12-24 Southern Research Institute Method of potentiating an immune response
US5133974A (en) 1989-05-05 1992-07-28 Kv Pharmaceutical Company Extended release pharmaceutical formulations
US5391723A (en) 1989-05-31 1995-02-21 Neorx Corporation Oligonucleotide conjugates
US5399346A (en) 1989-06-14 1995-03-21 The United States Of America As Represented By The Department Of Health And Human Services Gene therapy
EP0464533B1 (de) 1990-06-28 1998-07-29 Hoechst Aktiengesellschaft Fusionsproteine mit immunglobulinanteilen, ihre Herstellung und Verwendung
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
GB9019812D0 (en) 1990-09-11 1990-10-24 Scotgen Ltd Novel antibodies for treatment and prevention of infection in animals and man
US5407686A (en) 1991-11-27 1995-04-18 Sidmak Laboratories, Inc. Sustained release composition for oral administration of active ingredient
DE69334275D1 (de) 1992-08-21 2009-05-20 Univ Bruxelles Immunoglobuline ohne Leichtkette
US5645829A (en) 1993-06-18 1997-07-08 Beth Israel Hospital Association Mesothelial cell gene therapy
EP0804249A2 (en) 1994-03-15 1997-11-05 Brown University Research Foundation Polymeric gene delivery system
US5534615A (en) 1994-04-25 1996-07-09 Genentech, Inc. Cardiac hypertrophy factor and uses therefor
US5736152A (en) 1995-10-27 1998-04-07 Atrix Laboratories, Inc. Non-polymeric sustained release delivery system
US5898031A (en) 1996-06-06 1999-04-27 Isis Pharmaceuticals, Inc. Oligoribonucleotides for cleaving RNA
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
US6787136B1 (en) * 1999-09-03 2004-09-07 The Brigham And Women's Hospital, Inc. Methods and compositions for treatment of inflammatory disease using cadherin-11 modulating agents
KR20080023768A (ko) 2000-03-30 2008-03-14 화이트헤드 인스티튜트 포 바이오메디칼 리서치 Ｒｎａ 간섭의 ｒｎａ 서열 특이적인 매개체
US20030190598A1 (en) 2000-05-26 2003-10-09 Jasmid Tanha Single-domain antigen-binding antibody fragments derived from llama antibodies
CN100523215C (zh) 2000-12-01 2009-08-05 马普科技促进协会 介导rna干涉的小rna分子
JP2004245842A (ja) * 2003-02-14 2004-09-02 Seikagaku Kogyo Co Ltd 嚢胞性肺線維症の評価方法
GB0521621D0 (en) * 2005-10-24 2005-11-30 Domantis Ltd Tumor necrosis factor receptor 1 antagonists for treating respiratory diseases
EP2135078B1 (en) 2007-03-09 2013-08-21 DiscoveRx Corporation Methods for identifying agents and their use for the prevention or stabilization of fibrosis
WO2009055864A1 (en) * 2007-10-31 2009-05-07 Crc For Asthma And Airways Ltd Methods and compositions for regulating airway tissue remodelling
CA2711394A1 (en) * 2008-01-11 2009-07-16 Synovex Corporation Cadherin-11 antagonists and methods for the treatment of inflammatory joint disorders
JP2011514318A (ja) * 2008-02-11 2011-05-06 ノバルティス アーゲー カドヘリン１１（ｃｄｈ１１）アンタゴニストの使用方法
US9599603B2 (en) * 2008-07-16 2017-03-21 Case Western Reserve University Methods and compositions for modulating adhesion and migration of cadherin expressing cells

Also Published As

Publication number Publication date
EP2566967B1 (en) 2016-07-06
WO2011140173A1 (en) 2011-11-10
KR20130107203A (ko) 2013-10-01
AU2011248184A1 (en) 2012-12-20
EP3138915A1 (en) 2017-03-08
EP2566967A1 (en) 2013-03-13
AU2016201644A1 (en) 2016-04-07
EP2566967A4 (en) 2013-10-02
IL265950A (en) 2019-05-30
JP2016172738A (ja) 2016-09-29
AU2011248184B2 (en) 2015-12-17
JP2013531619A (ja) 2013-08-08
ES2596431T3 (es) 2017-01-09
AU2018200312A1 (en) 2018-02-01
JP5911848B2 (ja) 2016-04-27
CA2805267C (en) 2019-07-30
CA2805267A1 (en) 2011-11-10
AU2016201644B2 (en) 2017-12-14
JP6437946B2 (ja) 2018-12-12
IL222841A0 (en) 2012-12-31
JP2019031513A (ja) 2019-02-28
KR20190000385A (ko) 2019-01-02

Similar Documents

Publication Publication Date Title
IL273889A (en) Providing therapeutic agents to the central nervous system
ZA201109334B (en) Dosage forms of apixaban
ZA201400501B (en) New abuse-resistant pharmaceutical composition for the treatment of opioid dependence
HUE052944T2 (hu) Terápiás hatóanyagok központi idegrendszerbe juttatása
PL2902384T3 (pl) Postać chlorowodorku iwabradyny
IL228078A0 (en) Methods for administration of cell 7 integrin antagonists
PL2642993T3 (pl) Kompozycje rotygotyny lub farmaceutycznie dopuszczalnych soli rotygotyny
SG11201401287SA (en) Methods of treating liver conditions using notch2 antagonists
EP2648519A4 (en) NEW POLYMORPH OF NILOTINIB HYDROCHLORIDE
PL3287131T3 (pl) Terapeutyczne zastosowania ektoiny
IL245995A0 (en) Prophylactic or medical agent for fibrosis
EP2601200A4 (en) PREPARATION FROM PRASUGRELHYDROCHLORIDE
PL2407155T3 (pl) Formulacje inekalcytolu
EP2563923A4 (en) COMPOSITIONS AND METHODS FOR REDUCING SCARS AND TREATING FIBROSIS
GB201001203D0 (en) Use of pharmaceutically active compounds
EP2536688A4 (en) STABLE DOSAGE FORMS OF LEVOMILNACIPRAN
TWM401347U (en) Improved structure of brush
GB201100786D0 (en) Pharmaceutical compositions of immunosuppressants
PL395425A1 (pl) Sposób wytwarzania chlorowodorku 2-amino-N-tert-butylo-2- cyjanoacetamidu
GB201021622D0 (en) Preparation of N-Formyl benzotriazoles
GB201004479D0 (en) Therapeutic use of new compounds I
GB201009614D0 (en) Therapeutic use of compounds
TWM385568U (en) Structure of net-washing machine
TWM390786U (en) Improved structure of massage bat
GB201004480D0 (en) Therapeutic use of new compounds II

Legal Events

Date Code Title Description
FF Patent granted
KB Patent renewed